RESEARCH PAPER
Influenza vaccination in HIV-infected patients
Submission date: 2019-01-07
Acceptance date: 2019-03-05
Publication date: 2019-03-28
HIV & AIDS Review 2019;18(1):44-49
KEYWORDS
TOPICS
ABSTRACT
Introduction:
One of the most serious threats for people infected with human immunodeficiency virus (HIV) is the risk of influenza co-infection and complications thereof. Not only is this population fundamentally more susceptible to flu but also prolonged replication and excretion of the virus, longer illness period, higher complication rate, flu-associated mortality, and risk of cardiovascular disease have all been noted.
Material and methods:
The aim of our study was to assess vaccine efficacy against influenza in HIV-infected patients in various stages of the disease in comparison to a control group and estimate the influence of the vaccine on respiratory system infection rates. We prospectively studied 78 patients. Our study group included 47 patients with HIV and 31 healthy volunteers. The participants were immunised with TIV (trivalent influenza vaccine). Humoral response as an anti-AH1N1 (A/Brisbane/59/07), -AH3N2 (A/Brisbane/10/07), and -B strain (B/Florida/4/06) haemagglutinin antibody titre was measured. The assay was performed twice: before administration of the vaccine and a month after.
Results:
The HIV-infected group exhibited a weaker immune response than the control group; however, the immunisation did provide partial protection against influenza. Vaccine efficacy was similar, regardless of CD4 count. Trivalent influenza vaccine successfully prevented influenza-associated bacterial pneumonia.
Conclusions:
The study demonstrates that routine vaccination against influenza in HIV-infected patients, regardless of immune system deficiency, is substantiated.
One of the most serious threats for people infected with human immunodeficiency virus (HIV) is the risk of influenza co-infection and complications thereof. Not only is this population fundamentally more susceptible to flu but also prolonged replication and excretion of the virus, longer illness period, higher complication rate, flu-associated mortality, and risk of cardiovascular disease have all been noted.
Material and methods:
The aim of our study was to assess vaccine efficacy against influenza in HIV-infected patients in various stages of the disease in comparison to a control group and estimate the influence of the vaccine on respiratory system infection rates. We prospectively studied 78 patients. Our study group included 47 patients with HIV and 31 healthy volunteers. The participants were immunised with TIV (trivalent influenza vaccine). Humoral response as an anti-AH1N1 (A/Brisbane/59/07), -AH3N2 (A/Brisbane/10/07), and -B strain (B/Florida/4/06) haemagglutinin antibody titre was measured. The assay was performed twice: before administration of the vaccine and a month after.
Results:
The HIV-infected group exhibited a weaker immune response than the control group; however, the immunisation did provide partial protection against influenza. Vaccine efficacy was similar, regardless of CD4 count. Trivalent influenza vaccine successfully prevented influenza-associated bacterial pneumonia.
Conclusions:
The study demonstrates that routine vaccination against influenza in HIV-infected patients, regardless of immune system deficiency, is substantiated.
REFERENCES (33)
1.
Trovato M, D’Apice L, Prisco A, de Bernardinis P. HIV vaccination: a roadmap among advancements and concerns. Int J Mol Sci 2018; 19: E1241.
2.
Zanetti AR, Amendola A, Besana S, et al. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002; 20: B29-32.
3.
Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at residential facility in New York City. Clin Inf Dis 2001; 32: 1784-1791.
4.
Radwan HM, Cheeseman SH, Lai KK, et al. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000; 31: 604-606.
5.
Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161: 441-446.
6.
Neuzil KM, Reed GW, Mitchel EF Jr, et al. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281: 901-907.
7.
Conley LJ, Bush TJ, Buchbinder SP, et al. The association between cigarette smoking and selected HIV-related medical condictions. AIDS 1996; 10: 1121-1126.
8.
Beyer WEP, Palache AM, Lüchters G, et al. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately express seroresponse to influenza vaccination? Virus Res 2004; 103: 125-132.
9.
Esposito S, Franco E, Gavazzi G, et al. The public health value of vaccination for seniors in Europe. Vaccine 2018; 36: 2523-2528.
10.
Hirota Y, Kaji M, Ide S, et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 1997; 15: 962-967.
11.
Brydak LB. Pandemic of flu – myth or real threat? Oficyna Wydawnicza RYTM, Warszawa 2008.
12.
Commission of the European Communities. The rules governing medicinal products in the European Community. Commission Eur Commun 1992; 3: 93-98.
13.
Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (revision). 1997: CPMP/BWP/214/96.
14.
Brydak LB, Białek J, Rudnicka H, et al. Seroconversion assessment in billeted Military Medical University student group after anti influenza subunit vaccinations in 1993/1994 in Poland. Antiinfect Drugs Chemother 1997; 15: 13-16.
15.
Anema A, Mills E, Montaner J, et al. Efficacy of influenza vaccination in HIV-positive patients: a systemic review and meta-analysis. HIV Med 2008; 9: 57-61.
16.
Tasker SA, Treanor JJ, Paxton WB, et al. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 430-433.
17.
Yamanaka H, Teruya K, Tanaka M, HIV/Influenza Vaccine Study Team, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39: 167-173.
18.
Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011; 52: 128-137.
19.
Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta- analysis. BMC Infect Dis 2006; 6: 138.
20.
Brydak LB, Hryniewicz HJ, Machala M, et al. Humoral response to influenza vaccination in HIV-infected patients. Clin Drug Invest 1999; 17: 441-449.
21.
Amu S, Ruffin N, Rethi B, et al. Impairment of B-cell functions during HIV-1 infection. AIDS 2013; 27: 2323-2334.
22.
Rubin LG, Levin MJ, Ljungman P, Infectious Diseases Society of America, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 8: e44-100.
23.
Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18: 3040-3049.
24.
Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995; 182: 1727-1737.
25.
Cooper C, Hutton B, Fergusson D, et al. A review of influenza vaccine immunogenicity in HIV-infected adults. Can J Infect Dis Med Microbiol 2008; 19: 419-423.
26.
Huang KL, Ruben FL, Rinaldo CR Jr, et al. Antibody responses after influenza and pneumococcal immunization in HIV infected homosexual men. JAMA 1987; 257: 2047-2050.
27.
Miotti PG, Nelson KE, Dallabetta GA, et al. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989; 262: 779-783.
28.
Chadwick EG, Chang G, Decker MD, et al. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus infected children. Pediatr Infect Dis J 1994; 13: 206-211.
29.
Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52: 138-146.
30.
Walter ND, Taylor TH, Shay DK, Thompson WW, Active Bacterial Core Surveillance Team, et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis 2010; 50: 175-183.
31.
Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333-1340.
32.
Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-186.
33.
Vu T, Farish S, Jenkins M, et al. A meta-analysis of effectiveness of influenza vaccine in person aged 65 years and over living in the community. Vaccine 2002; 20: 1831-1836.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
